La science pour la santé
From science to health
Contents

• Address major biomedical research challenges
• Take action to improve the health of all
• Disseminate knowledge for the benefit of all
Address major biomedical research challenges
Address major biomedical research challenges

Be a reference in biomedical research

<table>
<thead>
<tr>
<th>in Europe and worldwide</th>
<th>in France</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 6,500 international cooperations with more than 100 countries</td>
<td>• 263 Research Units</td>
</tr>
<tr>
<td>• 33 European and international research projects or networks</td>
<td>• 34 Clinical Investigation Centers</td>
</tr>
<tr>
<td>• 2 Inserm Units</td>
<td>• 40 Service Units</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13,803 staff</th>
<th>A budget of €993 million</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 5,047 civil servants (2,144 researchers, ATIP-Avenir contracts included)</td>
<td>€658 million from government subsidies and €335 million from external resources</td>
</tr>
<tr>
<td>• 3,257 contract staff and temporary workers (incl. ATIP-Avenir contracts)</td>
<td></td>
</tr>
<tr>
<td>&gt; 45 ATIP-Avenir contracts</td>
<td></td>
</tr>
<tr>
<td>• 5,499 university-hospital practitioners and university staff</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patents and licenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>• A portfolio of 2,069 patent families</td>
</tr>
<tr>
<td>• 110 new license agreements signed</td>
</tr>
<tr>
<td>• 326 R&amp;D partnerships</td>
</tr>
</tbody>
</table>
Address major biomedical research challenges

Be a reference in biomedical research (2)

**Worldwide and in Europe**
- 9th most innovative public research organization worldwide in 2019
- No. 1 academic applicant in the biomedical sector and No. 2 in the biotechnology sector in Europe
- No. 1 European applicant in the pharmaceutical sector

**Close dialogue**
with over 500 patient organizations for
- participatory research
- meetings and debates between patients and researchers

- 384 H2020 contracts, 146 within the Health challenge and 35 coordinated by Inserm (No. 1 in Europe)
- 82 ERC grant recipients
- 45 Marie Skłodowska-Curie individual grants and participation in 44 innovative training networks (ITN)

**13,234 original articles**
• Address major biomedical research challenges

Make changes to adapt

1964
Inserm is created

1983
Public scientific and technological institute, entirely dedicated to human health and biomedical research

Placed under the joint authority of the French Ministries of Health and Research

2009
Inserm, following reform, ensures the strategic, scientific and operational coordination of biomedical research

Aviesan, the French National Alliance for Life Sciences and Health, is created

2011

2014
Inserm establishes its 2021-2025 Objectives and resources contract

Inserm celebrates its 50th anniversary

2019
Inserm establishes its 2025 Strategic plan with the French State

2021
Inserm establishes its 2021-2025 Objectives and resources contract

Inserm celebrates its 50th anniversary
Address major biomedical research challenges

Our organization

- Ethics Committee
- Ethics Evaluation Committee
- Scientific Integrity Office
- Think Tank Network with Patient Organizations (GRAM)
- History Committee

Vice CEO for Strategy
Thomas Lombès

Chairman and CEO
Gilles Bloch

Vice CEO for Administration
Damien Rouset

Management Board
- Scientific Advisory Board
- Specialized Scientific Committees
- Research Support Committee

Thematic Institutes
- Neurosciences, Cognitive Sciences, Neurology, Psychiatry
- Cancer
- Immunology, Inflammation, Infectious Diseases and Microbiology
- Pathophysiology, Metabolism, Nutrition
- Public Health
- Health Technologies
- Molecular and Structural Basis of Living Organisms
- Cell Biology, Development and Evolution
- Genetics, Genomics and Bioinformatics

Divisions
- Financial Affairs
- Legal Affairs
- Program Assessment and Follow-Up
- Scientific Information and Communication
- Partnership and External Relations
- Human Resources
- Information Systems
- Chief Accounting Department

Regional Offices
- Île-de-France (4)
- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Occitanie Méditerranée
- Occitanie Pyrénées
- Nord-Ouest
- Nouvelle-Aquitaine
- Provence, Alpes, Côte d’Azur and Corsica
Our presence in France

- Address major biomedical research challenges

261 Research Units
34 Clinical Investigation Centers
Address major biomedical research challenges

Our presence in France

14 Research universities in which Inserm invests more than €10M each year

83% of Inserm strengths
Our main partners

• 34 universities

• A key partner of 14 research universities in which Inserm invests more than €10M each year

• On 15 Idex and I-sites, Inserm invests 77% of its resources

• Research Units in 30 teaching hospitals

• Founding members of Aviesan alongside Inserm: CEA / CNRS / INRAE / INRIA / Institut Pasteur / IRD / CPU / CHRU and the associate members

• Other alliances: AllEnvi, Allistène, Athéna

• Industry: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi…

• Foundations and associations: Fondation Bettencourt Schueller, FRM…

• European and international academic institutions: Helmholtz…

Address major biomedical research challenges
Address major biomedical research challenges

Our presence in Europe

- Research teams: informal *scientific cooperation* with their partners
- Institutional *partnership agreements* and *specific collaborative networks* in Europe: 7 European laboratories within the International Research Project (IRP) program and 6 European laboratories within an International Research Network (IRN)
• Address major biomedical research challenges

Our presence in the world

• Research teams: informal **scientific cooperation** with their partners
• Institutional **partnership agreements** and **specific collaborative networks** outside Europe: 23 non-European laboratories within the International Research Project (IRP) program and 4 non-European laboratories within 2 International Research Networks (IRN)
Take action to improve the health of all
Our missions for health

- Take action to improve the health of all

**INITIATE, DEVELOP AND COORDINATE BIOMEDICAL RESEARCH OF EXCELLENCE**

- **Produce and disseminate knowledge** nationally and internationally
- **Play a major role in the national coordination of health research**
- **Provide scientific expertise and support for science based policy in health**
- **Create value from discoveries and their applications**
- **Support higher education and research training**
Our fields of activity and expertise

- Fundamental research
- Clinical and preclinical trials
- Cohorts and epidemiological studies
- Provision of expertise and contribution to public health and research policy
- Biomedical research infrastructure
- Technology transfer
Cohorts and epidemiological studies

Over 1.6 million people (2% of the French people) participating in Inserm cohorts

EpiCOV
- 130,000 volunteers for research on SARS-CoV-2

ELFE
- 20,000 children born in 2011. Longitudinal study from birth to adult age

Constances
- 200,000 subjects representative of the French population, aged 18 to 69 years + a biobank of 100,000 subjects

RaDiCo
- over 5,000 people with rare diseases in 12 cohorts

Major public health expertise and research databases, accessible online

Epidemiologie-France portal
- French health database catalogue
  > epidemiologie-france.aviesan.fr

CépiDc
- Epidemiology center on the medical causes of death
  > cepidc.inserm.fr

Orphanet
- Portal for rare diseases and orphan drugs
  > orpha.net

Take action to improve the health of all
A continuum from basic to clinical, therapeutic, and public health research

<table>
<thead>
<tr>
<th>Basic Research</th>
<th>Preclinical Studies</th>
<th>Clinical Investigation Centers</th>
<th>Pharmaceutical companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proof of concept</td>
<td>Phase I Ila</td>
<td>34 Clinical Investigation Centers</td>
<td>261 Research Units</td>
</tr>
<tr>
<td></td>
<td>Phase IIb III</td>
<td></td>
<td>Nationales Research infrastructures</td>
</tr>
<tr>
<td></td>
<td>Phase IV</td>
<td></td>
<td>About 90 cohorts &amp; Large Scale Studies</td>
</tr>
</tbody>
</table>
Value creation activities which are bearing fruit

- **2,069** patent families portfolio
- **147** new patent families in 2020
- An annual budget of **€1.4 M** to fund project maturation or proof of concept
- A maturation budget reaching **€20.3 M** invested in 307 projects since 2009
- **€408 M** industrial partnerships since 2006 incl. **€37.3 M** in 2020 (1/3 patent licensing, 2/3 research contracts)
- **€6-12 M** per year from licensing agreements
- Over **400** technologies available for licensing
- Strategic alliances with, for example: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi
- 10 start-ups created each year via Inserm Transfert (Inserm’s subsidiary)
- Partnerships with SATT
Inserm/Inserm Transfert in 2020 rankings

- 1st patent applicant at EPO in pharmaceuticals (5th year)*
- 2nd in the biotechnology sector (1st year)*
- 1st research academic institution in the biomedical sector *
- 2,069 patent families as of 31/12/2020

* European Patent Office (EPO) 2020 rankings
Take action to improve the health of all

Inserm Transfert: partnering with industries

Some of our industrial partners: Privileged partner of major industrials, mid-size, SME, involved in human health, at the international level
• Take action to improve the health of all

Inserm spin-offs based on inventors as drivers
Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- **the first prenatal diagnostic tests**;
- **understanding the HLA system and the ensuing immune reactions**;
- **the first in vitro fertilization**;
- **identification of HIV**;
- **radiotherapy for cancer**;
- **the first skin graft**;
- **deep brain stimulation** in the treatment of Parkinson’s disease;
- **gene therapy**…
Disseminate knowledge for the benefit of all
Collective expert reviews and contribution to public health policy

Inserm fulfils its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.
Our work with patient organizations

A mission to forge closer links between Inserm and over 500 patient organizations

- Facilitate access to scientific information for patients through training
- Promote events and direct dialogue between researchers and patient organizations
- Relay the concerns and needs of society to Inserm's management
- Engage for better collaboration of researchers with patient organizations in the evaluation process
Our presence in the service of public information

- Disseminate knowledge for the benefit of all

- **inserrm.fr**
  - 9,280,000 sessions

- **LinkedIn**
  - 84,000 followers

- **Twitter**
  - 145,000 followers

- **Facebook**
  - 39,000 followers

- **Instagram**
  - 8,000 followers

- **YouTube**
  - 180,000 followers

---

- **Santé en questions**
  - 10,000 participants

- **Lecture circuit**
  - + than 1,5 million participants and views

- **Public events**
  - 1,100 participants

- **Patient organization training seminars**
  - + than 1.3 million views

- **Canal Détox, information videos and articles**
  - + than 1.3 million views

*2020 figures*
#LaSciencePourLaSanté